Two Sigma Advisers’s Insys Therapeutics, Inc. INSY Stock Holding History

Two Sigma Advisers’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,000	Closed	-$74K	–	2521
2019 Q1	$74K	Buy	16,000 +900	+6%	+$4.26K	﹤0.01%	2215
2018 Q4	$53K	Buy	+15,100	New	+$105K	﹤0.01%	2272
2017 Q1	–	Sell	-70,200	Closed	-$646K	–	2529
2016 Q4	$646K	Buy	70,200 +23,900	+52%	+$270K	﹤0.01%	1745
2016 Q3	$546K	Sell	46,300 -44,400	-49%	-$675K	﹤0.01%	1640
2016 Q2	$1.17M	Sell	90,700 -11,700	-11%	-$171K	0.01%	1092
2016 Q1	$1.64M	Buy	102,400 +48,700	+91%	+$925K	0.01%	885
2015 Q4	$1.54M	Buy	53,700 +46,600	+656%	+$1.29M	0.01%	841
2015 Q3	$214K	Sell	7,100 -58,200	-89%	-$2.14M	﹤0.01%	1615
2015 Q2	$2.35M	Buy	+65,300	New	+$2.03M	0.02%	733
2014 Q2	–	Sell	-47,098	Closed	-$976K	–	2796
2014 Q1	$976K	Buy	+47,098	New	+$934K	0.01%	1171

Other funds holding INSY

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Two Sigma Advisers's INSY Position: Q2 2019 in Review

Two Sigma Advisers sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 16,000 shares — an estimated $74K sold.

Two Sigma Advisers first reported a position in INSY in Q1 2014 and held it in 10 quarters. The position peaked at $2.35M in Q2 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

Two Sigma Advisers reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Two Sigma Advisers sold 16,000 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $74K.
Two Sigma Advisers first reported a position in Insys Therapeutics, Inc. in Q1 2014 and held it in 10 quarters.
Two Sigma Advisers's Insys Therapeutics, Inc. position peaked at $2.35M in Q2 2015.
16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Two Sigma Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.